Biocytogen Partners with Acepodia to Develop Bispecific Antibody and Dual-Payload ADCs to Treat Complex Tumors
Shots:
- Biocytogen & Acepodia have entered into a strategic collaboration to evaluate dual-payload bispecific antibody-drug conjugate (BsAD2C) program in complex tumors by combining the former's RenLite platform with Acepodia's Antibody-Dual-Drugs Conjugation (AD2C) tech
- Under the agreement, Biocytogen will provide a bispecific antibody from its RenLite platform, while Acepodia will combine 2 distinct payloads using its AD2C platform
- The AD2C platform uses bio-orthogonal click chemistry for precise, site-selective payload conjugation without altering antibody integrity, enabling optimal Drug-to-Antibody Ratio (DAR) for potency and safety
Ref: Biocytogen | Image: Acepodia & Biocytogen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
